Cosmo Bio Co., Ltd. (3386) Price & Analysis

Compare

0 Followers

3386 Stock Chart & Stats

¥1190.00

¥2.00(0.18%)

At close: Jan 08 4:00 PM EST

¥1190.00

¥2.00(0.18%)

Day’s Range― - ―

52-Week Range¥971.00 - ¥1,486.00

Previous CloseN/A

Volume2.50K

Average Volume (3M)81.79K

Market Cap

¥7.92B

Enterprise Value¥5.00B

Total Cash (Recent Filing)¥3.19B

Total Debt (Recent Filing)¥20.00M

Price to Earnings (P/E)29.3

Beta0.31

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield4.57%

Share Statistics

EPS (TTM)11.30

Shares Outstanding6,048,000

10 Day Avg. Volume21,560

30 Day Avg. Volume81,793

Financial Highlights & Ratios

PEG Ratio0.70

Price to Book (P/B)0.79

Price to Sales (P/S)0.69

P/FCF Ratio20.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low Leverage / Strong Balance SheetAn extremely low debt load relative to equity gives enduring financial flexibility. It reduces bankruptcy risk, supports spending on R&D or inventory through cycles, and enables opportunistic M&A or capital returns without straining liquidity, strengthening long-term resilience.

Rebound In Cash Generation (2025)A sharp cash-flow rebound shows the business can convert revenues into usable cash after a weak year. Sustained OCF and FCF support reinvestment in products, steady dividend policy, and balance-sheet maintenance, increasing durability of strategic initiatives over multiple quarters.

Consistent Revenue GrowthSteady top-line expansion indicates persistent demand for research reagents and services. A growing revenue base provides scale advantages, supports fixed-cost absorption, and underpins long-term investment in product lines that align with secular life-science research funding trends.

Bears Say

Material Margin CompressionSubstantially lower margins and earnings indicate structural pressure on profitability, whether from pricing, cost inflation, or product mix shifts. If persistent, this erodes return on invested capital, limits reinvestment capacity, and weakens long-term shareholder value creation.

Historic Cash-flow VolatilityWide swings in free cash flow reduce predictability for capex, dividends and strategic spending. Volatility complicates multi-year planning and raises the risk that a future downturn could force cutbacks or delay investments critical to maintaining competitive position in research markets.

Weakened Shareholder Returns / ROE DeclineA meaningful fall in ROE signals declining efficiency in converting equity into profit. Persistently low ROE can deter capital allocation to higher‑return opportunities, may pressure management to change strategy, and could limit long-term investor support absent margin recovery.

3386 FAQ

What was Cosmo Bio Co., Ltd.’s price range in the past 12 months?

Cosmo Bio Co., Ltd. lowest stock price was ¥971.00 and its highest was ¥1486.00 in the past 12 months.

What is Cosmo Bio Co., Ltd.’s market cap?

Cosmo Bio Co., Ltd.’s market cap is ¥7.92B.

When is Cosmo Bio Co., Ltd.’s upcoming earnings report date?

Cosmo Bio Co., Ltd.’s upcoming earnings report date is May 13, 2026 which is in 67 days.

How were Cosmo Bio Co., Ltd.’s earnings last quarter?

Cosmo Bio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥11.3 earnings per share for the quarter, beating the consensus estimate of N/A by ¥11.3.

Is Cosmo Bio Co., Ltd. overvalued?

According to Wall Street analysts Cosmo Bio Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cosmo Bio Co., Ltd. pay dividends?

Cosmo Bio Co., Ltd. pays a Semiannually dividend of ¥25 which represents an annual dividend yield of 4.57%. See more information on Cosmo Bio Co., Ltd. dividends here

What is Cosmo Bio Co., Ltd.’s EPS estimate?

Cosmo Bio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cosmo Bio Co., Ltd. have?

Cosmo Bio Co., Ltd. has 6,048,000 shares outstanding.

What happened to Cosmo Bio Co., Ltd.’s price movement after its last earnings report?

Cosmo Bio Co., Ltd. reported an EPS of ¥11.3 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.148%.

Which hedge fund is a major shareholder of Cosmo Bio Co., Ltd.?

Currently, no hedge funds are holding shares in JP:3386

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cosmo Bio Co., Ltd.

Cosmo Bio Company,Limited engages in the import, export, manufacture, marketing, and sale of life science research biotools. Its life science research tools include reagents, kits, instruments, software, and diagnostics products. The company offers research reagents, such as antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, bacteria, and others, as well as offers detection reagents, cell and tissue culture systems, gene analysis systems, and others. It also provides research instruments comprising electrophoresis apparatuses, cell culture labware, gene manipulation systems, data analysis software, and others; drug discovery and custom research services; and clinical diagnostics. In addition, the company develops and manufactures cell/cell culture products, including adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, mesenchymal stem, and feeder cells, as well as tumor cell lines, coating reagents, macrophage-related products, etc.; and assay kit related products that comprise various measurement kits, staining kits, detection/purification kits, etc. Further, it offers biotechnology research equipment, which include constant-temperature transport containers, aluminum block mat heat insulation devices, dew condensation prevention glass plates, etc.; and consigned, custom peptide synthesis, and antibody production services. The company serves laboratories, research institutes, and life-science education and testing organizations. It sells its products through outlets in Japan, as well as a network of sales agents internationally. Cosmo Bio Company,Limited was founded in 1978 and is headquartered in Tokyo, Japan.